Heart failure & cardiomyopathies

Associations between cardiac resynchronization therapy and clinical outcomes according to the atrial fibrillation status in patients with heart failure with reduced ejection fraction

EuropacePublished Registry-based cohort study

Main finding · CV death/first HF hospitalizationResult — go to the resultHazard ratio 0.71 95% CI 0.64–0.79

Authors' conclusion

A diagnosis of AF was not associated with the likelihood of receiving CRT in real-world HF care, nor did it affect the association between CRT and lower risk of clinical outcomes.

Study context

Population
Patients with heart failure with reduced ejection fraction (HFrEF) meeting the guidelines' recommendation for cardiac resynchronization therapy (CRT), Swedish Heart Failure (HF) Registry, 2014–202224.7% received CRT
Participants
3,530 patients
Exposure
CRT vs no CRT, according to atrial fibrillation (AF) status
Outcome
Composite of:
  • Time to first HF hospitalization
  • Cardiovascular (CV) death
Methodological detailsSwedish HF Registry
  • Swedish HF Registry

Main finding

CV death/first HF hospitalization

Hazard ratio

0.71

95% CI 0.64–0.79

CRTvs No CRT
HR 0.71 (95% CI 0.64–0.79)

As reported in the abstract

Observational data: associations, not effects.

Secondary outcomes

OutcomeHR (95% CI)
All-cause deathRegardless of AF0.72 (0.64–0.81)

Individual components of the primary endpoint; total HF hospitalizations

CRT associated with lower adjusted risk of each component, but not with total number of HF hospitalizations

Likelihood of receiving CRT by AF (AF in 51.6%)

AF not associated with the likelihood of receiving a CRT

Original publication

Associations between cardiac resynchronization therapy and clinical outcomes according to the atrial fibrillation status in patients with heart failure with reduced ejection fraction. Europace. Published 18 November 2025. doi:10.1093/europace/euaf296

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.